Abstract 1135P
Background
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cancer of the skin, characterized by a high propensity for metastasis and a dismal prognosis particularly for advanced tumor stages. Immune-checkpoint blockade (ICB) is effective in MCC, but 60% of patients show primary or acquired resistance. Predictive biomarkers for the risk of metastasis and response to ICB are lacking. We studied the tumor microenvironment (TME) of 60 MCC patients to identify molecular mechanisms associated with response to ICB and profile the temporal dynamics occurring during tumor progression.
Methods
We collected 115 tissue biopsies from this MCC cohort with detailed clinical documentation and longitudinal follow-up and profiled the TME with high-plex imaging and matched bulk RNAseq that was collected from consecutive sections using laser-capture microdissection. We integrated clinical and molecular data and explored biomarkers using a lasso regressed CoxPH model.
Results
Our multi-modal data integration framework identified Merkel cell polyomavirus positivity, the abundance of CD8+ T cells and PD-L1+ macrophages as independent determinants of metastasis-free survival (DMFS), while the enrichment of cancer-associated fibroblasts at the tumor boundary correlated with distant metastasis. Response to ICB was correlated with the presence of central memory T cells (TCM), and Follicle-like cellular neighborhoods as well as a PD-L1+ tumor phenotype, that associated with an inflammatory macrophage signature (CXCL9, CXCL10, CXCL13) specifically at the tumor invasive front. By contrast, ICB failure associated with a cancer-stem phenotype (SOX2, NELL) and the downregulation of type-II interferon signaling (STAT1, JAK1). Last, we identified that exacerbation of T cell exhaustion, loss of TCM and inflammatory macrophages are critical elements of MCC evolutionary progression.
Conclusions
We demonstrate that high dimensional imaging of the MCC TME provides a framework to interrogate cellular interactions and tissue architecture in-situ at single-cell resolution. This framework enabled to identify genomic and phenotypic correlates for distant metastasis and response to ICB and map evolutionary changes during tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Deutsche Forschungsgemeinschaft.
Disclosure
G. Nolan: Financial Interests, Personal, Stocks or ownership: Akoya Bio. All other authors have declared no conflicts of interest.
Resources from the same session
1211P - IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Presenter: Heather Wakelee
Session: Poster session 04
1212P - IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)
Presenter: Enriqueta Felip
Session: Poster session 04
1213P - Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial
Presenter: Federico Cappuzzo
Session: Poster session 04
1214P - Imaging AI prognosis of early stage lung cancer using CT radiomics
Presenter: Ann Valter
Session: Poster session 04
1215P - United Kingdom (UK) real world study of adjuvant osimertinib in resected EGFR mutated lung cancer
Presenter: Raghad Elghadi
Session: Poster session 04
1216P - Adjuvant pembrolizumab therapy for completely resected stage I NSCLC with micropapillary or solid histological subtype
Presenter: Se-Hoon Lee
Session: Poster session 04
1217P - B cell infiltration and memory TOX+ CD8+ T cells in stage I-II non-small cell lung cancer (NSCLC) predict response to neoadjuvant pembrolizumab: A phase I study
Presenter: Jair Bar
Session: Poster session 04
1218P - FALCONS, a non-interventional retrospective study in resected NSCLC patients using the EPITHOR database, first analysis
Presenter: Marie Wislez
Session: Poster session 04
1219P - Integrating artificial intelligence (AI)-based lymphocytic infiltration assessment in early stage NSCLC: A sub-study of the TNM-I trial
Presenter: Falah Jabar
Session: Poster session 04
1220P - A phase III randomized trial investigating preventive effects of perioperative landiolol, a selective beta1 blocker, on the reduction of recurrence of completely resected NSCLC
Presenter: Yasuhiro Hida
Session: Poster session 04